INBS — Intelligent Bio Solutions Income Statement
0.000.00%
Last trade - 00:00- $8.75m
- $6.75m
- $3.11m
- 55
- 24
- 60
- 44
Annual income statement for Intelligent Bio Solutions, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.189 | 1.98 | 0.437 | 1.26 | 3.11 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 0.327 | 1.43 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.05 | 7.55 | 8.77 | 13.9 | 13.4 |
| Operating Profit | -2.86 | -5.57 | -8.34 | -12.6 | -10.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -3.19 | -7.06 | -8.33 | -10.7 | -10.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.19 | -7.06 | -8.33 | -10.7 | -10.2 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.16 | -7.04 | -8.31 | -10.6 | -10.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.16 | -7.04 | -8.31 | -10.6 | -10.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -82.1 | -154 | -136 | -77.3 | -6.38 |